Eli Lilly soars 15% after its breast cancer drug shows efficacy where a treatment from Pfizer failed (LLY, PFE)

· *Eli Lilly soared 14% on Tuesday after it announced that its breast cancer drug Verzenio was successful in meeting its primary endpoint in a Phase 3 trial.*
· *Verzenio was successful in preventing the recurrence of breast cancer for patients.*
· *Pfizer announced in late May that its competing drug Ibrance failed a...